Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics Limited has applied for quotation on the ASX of 73,508,717 new ordinary fully paid shares under the code NUZ, with an issue date of 29 January 2026, following previously announced transactions. The substantial new share issuance increases the company’s quoted capital base and may enhance its liquidity and financial flexibility, potentially supporting ongoing development programs and strengthening its position within the competitive therapeutics sector, while existing shareholders will need to assess the implications of the expanded share register on ownership dilution and market valuation.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company listed on the ASX under the code NUZ, operating in the therapeutics sector with a focus on developing and commercialising medical treatments. The company is part of the broader life sciences industry, targeting healthcare markets that demand innovative therapies for unmet medical needs.
Average Trading Volume: 490,012
Technical Sentiment Signal: Sell
Current Market Cap: A$80.46M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.